Thursday, February 11, 2016

GlaxoSmithKline gets Human Genome Sciences for $3 billion

GlaxoSmithKline says it has a deal to buy all of Human Genome Sciences for about $3 billion, which is $400 million more than the London-based drugmaker offered in April.

GlaxoSmithKline gets Human Genome Sciences for $3 billion


GlaxoSmithKline said Monday it has a deal to buy Human Genome Sciences for about $3 billion, which is $400 million more than the London-based drugmaker offered in April.

GSK has operations in Center City and the Philadelphia suburbs.

In April, GSK offered $2.6 billion, or $13 per share, for HGS, which is based in Rockville, Md.

GSK said in a statement Monday that it would pay $14.25 per share and that both company boards had approved the deal.

More coverage

The HGS management and board rejected the earlier offer, saying the company was worth much more.

The original conversation started friendly, but after the HGS rejection, shifted to hostile, with GSK going to HGS shareholders with the offer.

HGS said it was entertaining other offers, but there was skepticism in the market because three of HGS's top products are tied up in partnerships with GSK.

One of the three drugs, Benlysta, is the first new treatment for lupus in 50 years and was approved by the FDA.

Those partnerships meant another buyer would only get the HGS share of the partnership, which lessens the appeal.

GSK says the transaction values HGS at approximately $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt.

The $14.25 price represents a premium of 99% to the HGS closing price of $7.17 per share on April 18, which was the last day of trading before HGS publicly announced that GSK had made a private offer.

Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter